News - 02 Jul `20Vitiligo drug candidate goes to the finals of The Nature Spinoff Prize

New

Temprian Therapeutics, a spinoff from Northwestern University with patent for DNA-based vitiligo treatment, has made it to the finals of the Nature Spinoff Prize.

The 12 finalists represent companies from the United States, United Kingdom, Switzerland and Spain operating in pharmaceuticals, predictive assays and medical devices. Temprian’s selection as a finalist for the Nature Spinoff Prize provides hope for securing investment needed for a clinical trial. 

The judges will select four companies to participate in a live slam on 13 July. The winner will be awarded the title of 2020 Nature Spin-off Prize champion — and a grant of €30,000 (about US$34,000).

Details of Temprian’s innovation and its underlying patent Mutant HSP70i to Prevent Autoimmune Disease.

 



      FAQOther Questions

      • Is vitiligo contagious?

        Vitiligo is not contagious. This means it cannot be spread from person to person through physical contact, sharing personal items, or any other means of transmission. Vitiligo ...

      • What's the status with official recognition of World Vitiligo Day?

        In 2016, the United Nations marked World Vitiligo Day in its International Calendar of Disability Events. However, it was removed in 2019 when the calendar was streamlined to 'M...

      • How can I cure vitiligo?

        Currently, there is no cure for vitiligo. However, many treatments can help manage the condition by restoring skin pigmentation, halting the progression of depigmentation, and i...